Close Menu

NEW YORK (GenomeWeb) – Biocept said yesterday that it has closed a previously announced $10 million public offering.

The company sold 9.1 million shares of its common stock, as well as warrants to purchase up to 9.1 million shares at a combined offering price of $1.10 per share.

Underwriters also partially exercised an over-allotment, purchasing warrants for up to 627,131 additional shares of common stock at $0.0009 per warrant. These warrants are exercisable immediately at a price of $1.10 per share and will expire five years from the date of issuance, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that visa costs could prevent scientists and others from coming to the UK.

The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.

Nature News says some preprint repositories may close down due to a lack of funds to cover costs.

In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.